v3.26.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:              
Net loss $ (3,145,539) $ (2,152,471) $ (3,706,465) $ (3,053,007) $ (5,298,010) $ (6,759,472)  
Adjustments to reconcile net loss to net cash used in operating activities:              
Depreciation and amortization         1,266,791 29  
Change in fair value of derivative liabilities (48,785)   (11,673)   (125,049) (14,316)  
Amortization of debt discount and finance fees         12,122 29,927  
Financial advisor fee settled with Series B-1 Preferred Stock and Pre-Funded Warrants         857,390  
Stock-based compensation         27,507 583,899  
Interest payments on convertible notes accounted for at fair value         (60,377)  
Change in fair value of convertible notes   (213,930)   (121,451)  
Gain on extinguishment of debt (755,121)     (755,121)  
Changes in operating assets and liabilities:              
Prepaid expenses         (137,209) (83,472)  
Due to United Dogecoin         361,135  
Accounts payable and accrued expenses         807,542 545,099  
Accrued interest payable - related parties         (1,195)  
Change in operating lease asset and liabilities         (2,047) (650)  
Net cash used in operating activities         (2,984,949) (5,881,979)  
CASH FLOWS FROM INVESTING ACTIVITIES:              
Purchase of capitalized software         (72,000)  
Payment of installment payments related to Molecule.ai Asset Acquisition         (3,646,642)  
Payment of contingent consideration related to Molecule.ai Asset Acquisition         (1,750,000)  
Net cash used in provided by investing activities         (5,468,642)  
CASH FLOWS FROM FINANCING ACTIVITIES:              
Repayment of note payable-related party         (124,944)  
Proceeds from issuance of common stock and pre-funded warrants, net of placement agent costs         3,225,000 9,489,673  
Proceeds from PIPE Financing, net of issuance costs paid         5,000,000  
Payment of other issuance costs for issuance of common stock and equity-classified warrants         (15,750) (526,460)  
Proceeds from exercise of pre-funded warrants         574 19,652  
Payment of finance costs         (78,414)  
Net cash provided by financing activities         8,209,824 8,779,507  
Net change in cash and cash equivalents         (243,767) 2,897,528  
Cash and cash equivalents, beginning of period   $ 334,005   $ 1,920,144 334,005 1,920,144 $ 1,920,144
Cash and cash equivalents, end of period $ 90,238   $ 4,817,672   90,238 4,817,672 $ 334,005
Cash paid for:              
Interest         36,153  
Income taxes          
Supplemental non-cash financing activities:              
Issuance of Series B-1 Convertible Preferred Stock and 2026 Pre-Funded Warrants as a financial advisor fee         857,390    
May 2026 PIPE proceeds included in Investment in United Dogecoin         3,897,500  
Issuance costs in accounts payable and accrued expenses         525,503 32,675  
Issuance of Series B-1 Preferred Stock and pre-funded warrants pursuant to Molecule.ai Second Amendment         300,176  
Noncash prepayment of share repurchase pursuant to Molecule.ai Second Amendment         266,012  
Capitalized cost related to United Dogecoin replacement options         244,087  
Issuance of Series B-1 Convertible Preferred Stock and 2026 Pre-Funded Warrants pursuant to the United Dogecoin Merger Agreement         9,541,887  
Conversion of convertible notes accounted for at fair value         $ 121,750